![Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma | Oncology Practice Management Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma | Oncology Practice Management](http://d2geqc87xuuo99.cloudfront.net/web/OPM/201605_Vol6_No5/OPM_201605_Vol6_No5_Pg49_Tbl2_Vital_Sign_Abnormalities.png)
Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma | Oncology Practice Management
![Calcium phosphate engineered photosynthetic microalgae to combat hypoxic-tumor by in-situ modulating hypoxia and cascade radio-phototherapy [Abstract] Calcium phosphate engineered photosynthetic microalgae to combat hypoxic-tumor by in-situ modulating hypoxia and cascade radio-phototherapy [Abstract]](https://www.thno.org/v11/p3580/toc.jpg)
Calcium phosphate engineered photosynthetic microalgae to combat hypoxic-tumor by in-situ modulating hypoxia and cascade radio-phototherapy [Abstract]
![European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma | Business Wire European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma | Business Wire](https://mms.businesswire.com/media/20190827005768/en/134182/23/BMS.jpg)
European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma | Business Wire
![Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma - Clinical Lymphoma, Myeloma and Leukemia Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma - Clinical Lymphoma, Myeloma and Leukemia](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/03c03847-7438-43be-9032-3ba9500bffab/gr1_lrg.jpg)
Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma - Clinical Lymphoma, Myeloma and Leukemia
![Mechanism of action of anti-CS1 antibody (elotuzumab) against multiple... | Download Scientific Diagram Mechanism of action of anti-CS1 antibody (elotuzumab) against multiple... | Download Scientific Diagram](https://www.researchgate.net/profile/Joseph-Malaer/publication/319449283/figure/fig1/AS:542606296915968@1506378830248/Mechanism-of-action-of-anti-CS1-antibody-elotuzumab-against-multiple-myeloma-MM-A.png)